Comparative effect of angiotensin converting enzyme inhibitor versus angiotensin ii type i receptor blocker in acute myocardial infarction with non-obstructive coronary arteries; from the Korea Acute Myocardial Infarction Registry — National Institute of Health by Ahn, Joon Ho et al.
Address for correspondence:  Youngkeun Ahn, MD, PhD, FACC, FSCAI, Department of Cardiology, Cardiovascular Center, 
Chonnam National University Hospital, Institute of Molecular Medicine, BK21 Plus, Chonnam National University Medical 
School, 42 Jebong-ro, Dong-gu, Gwangju 61469, Korea, tel: 82-62-220-4764, fax: 82-62-224-4764, e-mail: cecilyk@hanmail.net
Received: 31.03.2020 Accepted: 21.07.2020 Early publication date: 28.09.2020
*The first two authors contributed equally.
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
clinicAl cARDiOlOGY
Cardiology Journal 
2021, Vol. 28, No. 5, 738–745
DOI: 10.5603/CJ.a2020.0130 





Comparative effect of angiotensin converting  
enzyme inhibitor versus angiotensin ii type i  
receptor blocker in acute myocardial infarction 
with non-obstructive coronary arteries; from the 
Korea Acute Myocardial infarction Registry  
— National institute of Health
Joon Ho Ahn1*, Ju Yong Hyun1*, Myung Ho Jeong1, Ju Han Kim1, Young Joon Hong1, 
Doo Sun Sim1, Min Chul Kim1, Hun-Sik Park2, Doo-Il Kim3, Seung-Ho Hur4,  
Seok Kyu Oh5, Youngkeun Ahn1; and other KAMIR-NIH Registry Investigators
1Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea 
2Department of Cardiology, Kyungpuk National University Hospital, Daegu, Korea 
3Department of Cardiology, Inje University Haeundae Paik Hospital, Busan, Korea 
4Department of Cardiology, Keimyung University Dongsan Hospital, Daegu, Korea 
5Department of Cardiology, Wonkwang University Hospital, Iksan, Korea
Abstract
Background: Selecting angiotensin converting enzyme inhibitor (ACEI) or angiotensin II type I re-
ceptor blocker (ARB) in patients diagnosed as acute myocardial infarction (AMI) with non-obstructive 
coronary arteries (MINOCA) is not established. The purpose of this study is to compare the clinical effect 
of ACEI vs. ARB in MINOCA patients. 
Methods and results: A total of 273 patients between November 2011 to June 2015, diagnosed with 
MINOCA who were registered in the Korea Acute Myocardial Infarction Registry — National Insti-
tute of Health were enrolled. Patients were divided into ACEI (n = 112) and ARB groups (n = 161). 
The primary endpoint was cumulative incidence of major adverse cardiac events (MACE) defined as 
cardiac death, recurrent MI, any new revascularization during 2 years clinical follow-up. Secondary 
endpoint was heart failure requiring re-hospitalization. Propensity score matching analysis was done. 
The incidence of primary endpoint was similar (10.4% vs. 15.6%, HR: 0.65; 95% CI: 0.29–1.47;  
p = 0.301) among both groups. However, the incidence of recurrent MI was significantly lower in ACEI 
group compared to ARB group (2.1% vs. 10.4%, HR: 0.18, 95% CI: 0.04–0.86; p = 0.031). 
Conclusions: In the present study, the risk and incidence of MACE was similar between ACEI and 
ARB therapy in MINOCA patients. However, ACEI significantly reduced the risk of recurrent MI. 
Further larger scale multi-center randomized clinical trials are needed to clarify the proper use of renin–  
–angiotensin–aldosterone system blocker in these patients. (Cardiol J 2021; 28, 5: 738–745)
Key words: non-obstructive coronary arteries, angiotensin converting enzyme inhibitor/ 
/angiotensin ii type i receptor blocker, prognosis 
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introduction
Over the past decades, a remarkable evolution 
has occurred in the field of interventional and phar-
macological modalities in acute myocardial infarc-
tion (AMI) [1]. Numerous coronary angiographic 
findings revealed that nearly 95% of AMI patients 
had obstructive coronary disease [2]. However, the 
remaining 5% and as many as 10% of AMI patients 
had no significant stenosis in their luminal coronary 
angiogram and these patients were coined as AMI 
with non-obstructive coronary arteries (MINOCA) 
[3]. Previous clinical studies demonstrated that 
MINOCA patients were younger and showed 
a higher portion of female patients compared to 
conventional patients with obstructive coronary 
artery disease (CAD) [4, 5]. The prognosis of 
MINOCA patients were known to be favorable over 
those with conventional obstructive CAD, however 
several recent reports demonstrated that the actual 
prognosis was not benign [6–8]. And yet, accurate 
evidence based therapeutic guidelines for these 
specific groups of patients is lacking [9]. Current 
guidelines strongly recommend (class I, level of 
evidence A) angiotensin converting enzyme in-
hibitor (ACEI) for MI patients with left ventricular 
ejection fraction (LVEF) of less than 40% or with 
symptoms of heart failure (HF) unless contrain-
dicated [1, 10]. Moreover, ACEI was encouraged 
for all ST-segment elevation MI patients without 
contraindications to their use (class IIa, level of 
evidence A). Guidelines also mentioned that the 
use of another renin–angiotensin–aldosterone 
(RAA) system blocker, angiotensin II type I recep-
tor blocker (ARB) should be spared to patients 
who were intolerant to ACEI (class I, level of 
evidence B). ARB is considered as an alternative 
choice. The main principle in MINOCA treatment 
is treating the underlying mechanism. However as 
previously mentioned, there are no evidence based 
therapeutic guidelines in treatment for MINOCA 
patients [11].
The purpose of the present study is to compare 
the clinical effect of ACEI and ARB in patients 
diagnosed as MINOCA in Korean AMI patients.
Methods
Among the 13,650 patients enrolled in Korea 
Acute Myocardial Infarction — National Institute 
of Health (KAMIR-NIH) between November 2011 
to June 2015, 704 patients that showed insignificant 
stenosis (< 50%) in their initial coronary angio-
gram were selected. The KAMIR-NIH is a prospec-
tive, open, multi-center, web-based cohort study 
to investigate the real-world outcome of Korean 
patients with AMI from 15 centers in Korea and has 
been supported by a grant of Korea Centers for Dis-
ease Control and Prevention since November 2011. 
Data were collected by trained study coordinators 
based on standardized protocol. Study protocol was 
approved by ethics committee at each participating 
institution. From these 704 individuals, the follow-
ing patients were excluded sequentially: 87 patients 
with definite diagnosis such as stress induced 
cardiomyopathy or myocarditis, 309 patients who 
have not received either ACEI nor ARB or both, 
35 patients who lacked outpatient follow-up data. 
A total of 273 patients were included in the present 
study. Patients were further divided into ACEI 
(n = 112) and ARB group (n = 161) (Fig. 1). The 
current study was conducted according to the Dec-
laration of Helsinki. The institutional review board 
of all participating centers approved the study pro-
tocol. The approval number was CNUH2011-172 
of Chonnam National University Hospital. Written 
informed consent was obtained from all participat-
ing patients.
Blood samples for baseline laboratory tests 
were collected in the emergency room before 
diagnostic coronary angiography was carried out. 
Coronary angiography was performed by a standard 
technique through either radial or femoral artery. 
All patients received 300 mg loading dose of acetyl-
salicylic acid (ASA) and 300–600 mg loading dose of 
KAMIR-NIH Registry
704 patients with insignicant
stenosis (< 50%) in coronary
angiogram




No ACEI or ARB












Figure 1. Study flow chart; ACEI — angiotensin con-
verting enzyme inhibitor; ARB — angiotensin receptor 
blocker; MINOCA — myocardial infarction with non-
-obstructive coronary artery disease.
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clopidogrel before the coronary angiography unless 
contraindicated. During the hospital period, other 
medications including beta-blocker, statin, and cal-
cium channel blocker (CCB) were also prescribed. 
Two-dimensional echocardiography was performed 
in all patients during the initial hospitalization 
period and LVEF was evaluated. 
Diagnosis was AMI was made according to the 
clinical presentation, 12-lead electrocardiogram 
findings and change in cardiac biomarkers. Patients 
were categorized as MINOCA if the diagnosis of 
AMI was made and the coronary angiographic find-
ings during initial hospitalization period showed no 
significant obstructive CAD (stenosis < 50%) [9]. 
In the present study, the primary end point was 
the cumulative incidence of major adverse cardiac 
events (MACE) during 2 years clinical follow up. 
MACE was composite of cardiac death, recurrent 
MI, and any new revascularization. The secondary 
end point was HF requiring re-hospitalization. All 
deaths were considered cardiac deaths if non-cardiac 
deaths were excluded. Recurrent MI was defined as 
recurrent symptoms with new ST-segment elevation 
in electrocardiogram or re-elevation of cardiac mark-
ers to at least twice the upper limit of normal [12]. 
Any new revascularization was defined as interven-
tional or surgical revascularization method including 
percutaneous coronary intervention or coronary 
artery bypass graft surgery.
Statistical analysis
The baseline clinical characteristics of both 
treatment group were analyzed. Continuous vari-
ables were presented as means ± standard devia-
tions and were compared by using unpaired the 
Student t-test or Mann-Whitney U test. Discrete 
variables were expressed as percentages and 
frequencies and were compared using chi-square 
statistics or the Fisher exact test. To minimize 
the selection bias in direct comparison between 
ACEI and ARB, propensity score analysis using 
multivariable logistic regression was done. Vari-
ables included were age, sex, atypical chest pain 
on admission, Killip class on admission, cardiovas-
cular risk factors (hypertension, diabetes mellitus, 
dyslipidemia, smoking status), previous angina, 
previous MI, previous cerebrovascular disease, 
laboratory findings (serum glucose, renal function 
test, cardiac enzymes, lipid profiles), LVEF and 
prescribed medications (ASA, clopidogrel, beta-
-blocker, statin, and CCB). Patients receiving ARB 
were matched 1 on 1 to the patients receiving ACEI 
with the nearest neighbor matching method (cali-
per width of 0.2 of the standard deviation). In the 
propensity score matched populations, the baseline 
characteristics were also analyzed. The risk of each 
clinical end point in both matched groups were 
compared by using the Cox proportional hazard 
regression model with covariables that showed 
statistical significance (p < 0.1) in univariable 
analysis or were considered clinically important 
in the multivariate model. Hazard ratio (HR) with 
95% confidence interval (CI) were calculated. 
All analyses were performed by using SPSS for 
Windows, version 25.0 (Armonk, NY). All statisti-
cal tests were 2-tailed with statistical significance 
defined as a p value ≤ 0.05.
Results
In the crude population, mean age of the both 
groups were 66.5 ± 13.3 years (ACEI group) 
and 68.0 ± 10.9 years (ARB group). ACEI group 
patients had a higher percentage of smokers 
(57.1% vs. 34.8%; p ≤ 0.001) and tended to have 
a wider history of previous angina (23.2% vs. 13.7%; 
p = 0.041). On the other hand, the ARB patient 
group had a higher portion of female patients 
(37.5% vs. 54.7%; p = 0.005) and had more medi-
cal history of hypertension (50.0% vs. 64.0%; 
p = 0.021). Estimated LVEF was significantly 
lower in the ACEI group compared to the ARB 
group (49.9 ± 13.4 vs. 55.5 ± 12.4; p ≤ 0.001). 
After propensity score matching, 96 matched pairs 
of patients were selected and there was no differ-
ence in baseline clinical characteristics in both the 
ACEI and ARB groups (Table 1).
During the 2 year clinical follow-up period, 
cumulative incidence of primary end point MACE 
was similar between the ACEI and ARB groups in 
the crude population (10.4% vs. 15.6%; p = 0.449). 
Also, no difference was observed in the incidence 
of cardiac death (7.1% vs. 4.3%; p = 0.561), re-
current MI (1.8% vs. 6.8%; p = 0.054), any new 
revascularizations (0.9% vs. 5.0%; p = 0.064) and 
HF requiring re-hospitalization (5.2% vs. 7.3%, 
HR: 0.42, 95% CI: 0.11–1.68, p = 0.220). After 
propensity score matching analysis, the incidence 
and risk of recurrent MI was significantly lower in 
the ACEI group compared to the ARB group (2.1% 
vs. 10.4%, HR: 0.18, 95% CI: 0.04–0.86, p = 0.031) 
(Table 2). Other independent clinical factors for 
2 years MACE were female sex (HR: 3.15, 95% CI: 
1.06–8.36; p = 0.039) and estimated glomerular 
filtration rate < 60 mL/min/1.73 m2 (HR: 3.85, 
95% CI: 1.36–9.89; p = 0.011) (Table 3). Kaplan-
-Meier curves for clinical outcomes are displayed 
in Figure 2.
www.cardiologyjournal.org 741
Joon Ho Ahn et al., ACEI versus ARB in MINOCA










Age [year] 66.5 ± 13.3 68.0 ± 10.9 0.327 66.3 ± 12.9 66.6 ± 11.7 0.860
Female 42 (37.5%) 88 (54.7%) 0.005 39 (40.6%) 39 (40.6%) 1.000
Atypical angina 31 (27.7%) 48 (29.8%) 0.702 27 (28.1%) 22 (22.9%) 0.408
Killip class III, IV 15 (13.4%) 11 (6.8%) 0.069 8 (8.3%) 9 (9.4%) 0.799
Risk factors:
Hypertension 56 (50.0%) 103 (64.0%) 0.021 50 (52.1%) 54 (56.3%) 0.562
Diabetes mellitus 30 (26.8%) 57 (35.4%) 0.133 28 (29.2%) 35 (36.5%) 0.282
Dyslipidemia 10 (8.9%) 14 (8.7%) 0.947 9 (9.4%) 12 (12.5%) 0.488
Previous angina 26 (23.2%) 22 (13.7%) 0.041 22 (22.9%) 18 (18.8%) 0.477
Previous MI 28 (25.0%) 30 (18.6%) 0.206 23 (24.0%) 23 (24.0%) 1.000
Previous CVA 7 (6.3%) 12 (7.5%) 0.701 7 (7.3%) 6 (6.3%) 0.774
Smoking 64 (57.1%) 56 (34.8%) < 0.001 50 (52.1%) 47 (49.0%) 0.665
Laboratory findings:
Serum glucose [mg/dL] 151.9 ± 74.9 155.5 ± 67.9 0.686 153.0 ± 75.4 159.2 ± 75.4 0.569
eGFR [mL/min/1.7 m2] 79.8 ± 29.4 82.5 ± 44.3 0.573 81.9 ± 28.9 80.9 ± 48.2 0.864
CK-MB [mg/dL] 35.7 ± 98.5 24.7 ± 41.9 0.265 27.4 ± 63.6 29.8 ± 50.8 0.768
Troponin I [mg/dL] 18.3 ± 74.4 7.8 ± 17.2 0.146 17.5 ± 79.2 9.7 ± 19.4 0.345
Total cholesterol [mg/dL] 163.2 ± 45.2 164.4 ± 43.9 0.821 161.5 ± 43.8 168.3 ± 50.8 0.317
Triglyceride [mg/dL] 114.5 ± 115.0 118.9 ± 85.1 0.713 126.4 ± 121.1 131.9 ± 99.7 0.333
HDL cholesterol [mg/dL] 50.3 ± 29.7 45.5 ± 14.2 0.074 47.7 ± 14.5 47.5 ± 15.9 0.937
LDL cholesterol [mg/dL] 94.6 ± 35.0 99.9 ± 31.9 0.189 92.4 ± 33.8 95.1 ± 36.1 0.486
LVEF [%] 49.9 ± 13.4 55.5 ± 12.4 0.001 52.1 ± 11.9 52.3 ± 12.5 0.993
Medications:
ASA 111 (99.1%) 158 (98.1%) 0.512 95 (99.0%) 94 (97.9%) 0.561
Clopidogrel 102 (91.1%) 141 (87.6%) 0.364 87 (90.6%) 86 (89.6%) 0.809
Beta-blocker 81 (72.3%) 108 (67.1%) 0.356 74 (77.1%) 68 (70.8%) 0.324
Calcium channel blocker 33 (29.5%) 47 (29.2%) 0.961 28 (29.2%) 29 (30.2%) 0.874
   Statin 94 (83.9%) 141 (87.6%) 0.392 81 (84.4%) 86 (89.6%) 0.284
Values are presented as the number (%) of patients or mean standard deviation. ACEI — angiotensin converting enzyme inhibitor; ARB — 
angiotensin receptor blocker; ASA — acetylsalicylic acid; CK-MB — creatine kinase-myocardial band isoenzyme; CVA — cerebrovascular 
accident; eGFR — estimated glomerular filtration rate; HDL — high density lipoprotein; LDL — low density lipoprotein; LVEF — left ventricular 
ejection fraction; MI — myocardial infarction
















 MACE*: 10 (8.9%) 19 (11.8%) 0.449 10 (10.4%) 15 (15.6%) 0.65 (0.29–1.47%) 0.301
Cardiac death 8 (7.1%) 7 (4.3%) 0.319 8 (8.3%) 6 (6.2%) 1.38 (0.46–4.12%) 0.561
Recurrent MI 2 (1.8%) 11 (6.8%) 0.054 2 (2.1%) 10 (10.4%) 0.18 (0.04–0.86%) 0.031
Any new revascularization 1 (0.9%) 8 (5.0%) 0.064 1 (1.0%) 5 (5.2%) 0.11 (0.01–1.38%) 0.085
HF re-hospitalization 7 (6.3%) 9 (5.6%) 0.819 5 (5.2%) 7 (7.3%) 0.42 (0.29–1.47%) 0.220
*Composite of cardiac death, recurrent MI, and any new revascularization. Values are presented as n (%) of patients or mean ± standard 
deviation. CI — confidence interval; HF — heart failure; HR — hazard ratio; MACE — major adverse cardiac event; other abbreviations as in 
Table 1.
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Discussion
Results of the present study indicate that 
risk of MACE was similar in MINOCA patients 
treated with either ACEI or ARB. However, after 
propensity score matching analysis, it was revealed 
that ACEI therapy significantly lowered the risk 
of recurrent MI compared to the ARB therapy in 
MINOCA patients. 
Table 3. Clinical predictors of major adverse cardiac event.
Adjusted HR (95% CI) P
Female 3.15 (1.06–8.36) 0.039
ACEI 0.79 (0.32–1.97) 0.613
eGFR < 60 mL/min/1.73 m2 3.85 (1.36–9.89) 0.011 
Abbreviations as in Tables 1 and 2.
Figure 2. Kaplan-Meier curves for major adverse cardiac event (MACE) (A), cardiac death (B), recurrent myocardial 
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Early angiographic studies carried out by De-
Wood et al. [2] demonstrated that more than 90% 
of AMI patients show obstructive CAD (≥ 50% 
stenosis) in their luminal coronary angiogram. 
Since then, there were emerging interests in the 
remaining 5–10% of the population group. Clini-
cians and interventional cardiologists defined this 
group of patients as MINOCA [9]. The proportion 
of MINOCA patients in the present study was 4.5%, 
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which was similar with the other previous reports. 
The following conditions should be included for 
a diagnostic approach to MINOCA: (i) Diagnostic 
criteria of AMI; (ii) No evidence of obstructive CAD 
(≥ 50% stenosis) in the initial coronary angiogra-
phy; (iii) The overt cause of a specific diagnosis 
at the time of initial clinical presentation must be 
absent [3, 13].
MINOCA patients are known to be younger 
and showed a higher percentage of female patients 
compared to patients with conventional obstructive 
CAD [4, 5]. A recent meta-analysis reported that 
mean age of MINOCA patients was 58.8 years and 
the mean age of obstructive CAD patients was 61.2 
years. 40% of MINOCA patients were women while 
only 24% were women in patients with obstructive 
CAD [5]. The proportion of female patients were 
47% in the crude population and 40.6% in the pro-
pensity matched population in the present study, 
which was similar to meta-analysis data. However, 
our patient’s mean age was older in both treatment 
groups (ACEI group: 66.5 ± 13.3 years, ARB group: 
68.0 ± 10.9 years) compared to the meta-analysis 
data. Early studies revealed that MINOCA patients 
had better clinical outcomes compared to those 
with conventional obstructive CAD [4, 6]. But, 
Kang et al. [14] showed that the incidence of 12 
month MACE including all-cause death, MI and 
ischemic target vessel revascularization was 7.8% 
which was nearly the same as one vessel or two 
vessel obstructive CAD. The incidence of 2 years 
MACE in the present study was 13%. This result 
could be considered to be higher than other results 
reported by Rossini et al. (9.1%) [15]. The higher 
proportion of conventional cardiovascular risk fac-
tors such as smoking status and diabetes mellitus 
could have been the main contributing factor.
The clinical importance of MINOCA should 
not be underestimated because the proportion of 
MINOCA patients is not small and this group of 
patients are younger than conventional groups 
of patients with obstructive CAD. Nevertheless, 
the current clinical treatment guideline of MINOCA 
treatment is lacking. As previously mentioned, the 
mainstay of MINOCA therapy is based on treating the 
underlying pathophysiologic mechanism. The exact 
pathophysiologic mechanism of MINOCA needs fur-
ther research but there are potential etiologic factors 
including plaque rupture or erosion, coronary artery 
spasm, coronary artery embolism or thrombus, mi-
crovascular dysfunction, etc. [11, 16, 17]. 
The benefit of long-term medical treatment in 
MINOCA patients was shown in several studies. 
An observational study of MINOCA patients in the 
Swedish Web-system for Enhancement and Devel-
opment of Evidence-based care in Heart disease 
Evaluated According to Recommended Therapy 
(SWEDEHEART) registry presented evidence of 
clinical benefit in long-term medical therapy for 
secondary prevention in MINOCA patients. Dur-
ing the mean follow up period of 4.1 years, there 
was an 18% risk reduction of primary outcomes in 
patients receiving RAA system blockers including 
ACEI or ARB [18]. However, there were no stud-
ies that directly compared the clinical effect of 
ACEI and ARB in MINOCA patients. According 
to available research, the current study is the first 
to directly compare the clinical effect between 
ACEI and ARB in MINOCA patients. The results 
showed that the incidence and risk of MACE in 
MINOCA patients were similar in the ACEI group 
and ARB group. The hard endpoint of cardiac death 
was similar in both treatment groups and this 
result was consistent with previous randomized 
clinical trials comparing ACEI and ARB [19, 20]. 
However, our results indicate that ACEI therapy 
lowered the risk of recurrent MI compared to the 
ARB therapy. These results could be inferred as 
a distinctive drug effect of ACEI by suppression 
of angiotensin II and bradykinin preservation and 
eventually resulted in restrained endothelial dys-
function [21, 22]. Another potential cause might be 
the deleterious effect by overstimulation of angio-
tensin type II receptor by ARB which also could 
lead to an increase in angiotensin II levels [23]. 
Based on these factors, we considered that ACEI 
should  be the first line treatment in MINOCA 
patients. Herein, we cautiously suggest that ACEI 
might be a preferable option in MINOCA patients 
because ACEI reduced the risk of recurrent MI 
compared to ARB.
Limitations of the study
The present study has several limitations. 
First, the study was not a randomized controlled 
clinical trial but a retrospective analysis based on 
a small sample sized population and selection bias 
might have existed. Although propensity score 
matching analysis was done and most potential 
confounders were adjusted for and analyzed, other 
variables that were associated with the clinical out-
comes might not have been included in the present 
study. Second, the heterogeneity of MINOCA was 
not considered and the registry data lacks other 
diagnostic modalities that clarifies the accurate 
underlying cause of MINOCA including cardiac 
magnetic resonance (CMR) imaging or intravas-
cular ultrasound, optical coherence tomography 
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[11, 16]. This was also the main shortcoming in 
the SWEDEHEART registry data and the they also 
stated that ideally the CMR proven myocarditis 
should have been excluded because one third of 
patients diagnosed as MI were actually discov-
ered to have combined myocarditis in their CMR 
findings [18, 24]. An effort was made to select 
true MINOCA patients by excluding 87 patients 
diagnosed as stress induced cardiomyopathy or 
myocarditis however, a more precise and detailed 
study is needed because the future treatment 
guideline would be focused on MINOCA patients 
with unidentified cause. Third, accurate data re-
flecting the 2 year drug compliance of patients and 
specific categorization of ACEI and ARB and its 
prescribed dosage is lacking in the present study. 
Further larger scale multi-center randomized 
clinical trials comparing the clinical effect of 
ACEI or ARB in MINOCA patients are needed for 
a proper RAA system blocking agent treatment 
in these groups of patients and to establish new 
treatment guidelines in MINOCA.
Conclusions
In the present study, the risk and incidence of 
MACE was similar between ACEI and ARB therapy 
in MINOCA patients. However, ACEI significantly 
reduced the risk of recurrent MI. Further larger 
scale multi-center randomized clinical trials are 
needed to clarify the proper use of RAA system 
blocker in these patients.
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